MedPath

TERUFLEX Blood Bag System Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1)

TERUFLEX BLOOD BAG SYSTEM with Blood Sampling Arm

Approved
Approval ID

6b6f4a15-7bb0-4092-b43d-b423f14ec12f

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 7, 2018

Manufacturers
FDA

Terumo Corporation

DUNS: 690543319

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1)

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code53877-001
Application NumberBN820528
Product Classification
M
Marketing Category
C73594
G
Generic Name
Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1)
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateDecember 7, 2018
FDA Product Classification

INGREDIENTS (6)

AdenineActive
Quantity: 0.275 g in 1000 mL
Code: JAC85A2161
Classification: ACTIB
Anhydrous Citric AcidActive
Quantity: 2.99 g in 1000 mL
Code: XF417D3PSL
Classification: ACTIB
SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATEActive
Quantity: 2.22 g in 1000 mL
Code: 593YOG76RN
Classification: ACTIB
Dextrose MonohydrateActive
Quantity: 31.9 g in 1000 mL
Code: LX22YL083G
Classification: ACTIB
WaterInactive
Code: 059QF0KO0R
Classification: IACT
Trisodium Citrate DihydrateActive
Quantity: 26.3 g in 1000 mL
Code: B22547B95K
Classification: ACTIM

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

TERUFLEX Blood Bag System Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1) - FDA Drug Approval Details